Compare Novartis AG (NVS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TG Therapeutics Inc — how do they compare? Novartis AG trades at $151.8 (market cap $291.04B), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: Novartis AG is far larger — about 38.4× TG Therapeutics Inc's market cap, and Novartis AG pays a 3.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NVS | TGTX | |
|---|---|---|
Market Cap | $291.04B | $7.58B |
Sector | Health | Health |
52-Week High | $168.62 | $59.06 |
52-Week Low | $121.20 | $26.94 |
Enterprise Value | $332.36B | $7.78B |
Dividend Yield | 3.11% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
